{"brief_title": "A Rheumatoid Arthritis (RA) Study Treating Signs and Symptoms of RA in People With RA & Receiving Methotrexate", "brief_summary": "This clinical study is investigating AMG 719, an investigational drug, for the treatment of patients who have Rheumatoid Arthritis and who are taking Methotrexate. AMG 719 is a drug which is self-injected beneath the skin (similarly to the way insulin is self-injected by diabetics). Patients on this study are on study for 28-weeks. They visit the study facility at least 11 times while participating in the study.", "condition": ["Rheumatoid Arthritis"], "intervention_type": ["Drug", "Drug", "Drug", "Drug", "Drug"], "intervention_name": ["Placebo", "AMG 719", "AGM 719", "AMG 719", "placebo to AMG 719"], "description": ["Placebo given 3 times weekly", "50 mg 3 times weekly", "200 mg 3 times weekly", "400 mg 3 times weekly", "Placebo dose given 3 times weekly"], "arm_group_label": ["Placebo", "50 mg", "200 mg", "400 mg", "Placebo"], "criteria": "- Men or women, at least 18 years of age at screening - Diagnosed with Rheumatoid Arthritis, with a disease duration of at least 24 weeks, receiving methotrexate, and having no recent history of substance or alcohol abuse", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "mesh_term": ["Arthritis", "Arthritis, Rheumatoid"], "id": "NCT00038298"}